Authorization & medical necessity required

Services must meet authorization and medical necessity guidelines for the procedure, diagnosis, and the member's state of residence; coverage does not guarantee reimbursement. Providers are responsible for accurate documentation and appropriate coding per industry standards. If coding/billing guidelines or current reimbursement policies are not followed, the claim may be denied or payment recouped.

• Coverage is determined by procedure, diagnosis, and member state of residence.
• Providers must submit accurate documentation and code according to industry standard coding guidelines.
• Noncompliance with coding/billing guidelines or reimbursement policies may lead to denial or recoupment.

Suggest prior authorization for non-guideline indications

When testing is requested for asymptomatic relatives, routine population screening, or for adult idiopathic VTE where guideline panels advise against routine testing, prior authorization may be required to justify clinical utility and medical necessity.

• Examples: asymptomatic family members, routine screening prior to oral contraceptives in general population, adult idiopathic VTE where testing is not routinely recommended.
• Prior authorization may be requested to document that results would change management.

Prior authorization may apply to thrombophilia assay CPTs

Procedure codes for antithrombin, protein C, protein S, and APC resistance assays are identified for reference; the payer may require prior authorization for these specific thrombophilia assay CPTs per local policy.

• Referenced CPTs include 85300, 85301, 85302, 85303, 85305, 85306, 85307.
• These codes are provided as reference; prior authorization requirements may vary by local policy.

No universal prior authorization specified in policy text

No specific, universal prior authorization requirements are specified in the cited policy text; local payer rules and member benefit documents should be checked for any plan- or state-level authorization requirements.

• Refer to member benefit documents and local payer policy for any applicable prior authorization rules.

Start with D-dimer before thrombophilia testing when appropriate

Use a stepwise diagnostic approach: consider D-dimer as the initial, non-genetic test to exclude PE/DVT in patients with low or intermediate pretest probability before pursuing thrombophilia panels when clinically appropriate.

• ASH and Anticoagulation Forum recommend starting with D-dimer in low/intermediate pretest probability populations.
• Reserve thrombophilia panels for situations where results will change management.

Apply validated clinical probability rules and age-adjusted D-dimer first

Use validated clinical decision rules (e.g., Wells score, Geneva, PERC) and age-adjusted D-dimer thresholds to triage imaging and further testing for suspected PE/DVT prior to ordering thrombophilia or advanced laboratory diagnostics.

• Age-adjusted D-dimer: >500 mcg/L for patients <50 years; > age x 10 for patients ≥50 years.
• Proceed to imaging when D-dimer is positive or clinical probability is high.

Accurate documentation and coding required

Providers must accurately document the clinical scenario and coding to support medical necessity; incomplete or incorrect documentation/coding may result in claim denial or recoupment.

• Document indication, timing relative to acute event and anticoagulation status, and how results will change management.
• Code claims according to industry standard coding guidelines to avoid denials.

Document guideline-supported clinical indications and timing

Document clinical details that match guideline-supported indications (for example, VTE at unusual sites, VTE provoked by pregnancy/postpartum, VTE associated with oral contraceptives when results will change management) and record timing of testing relative to anticoagulant therapy.

• Include personal and family history, site of VTE (unusual vs provoked), and rationale for testing.
• Record whether testing is deferred until after the acute phase or after anticoagulants have been held.

Defer testing until after anticoagulation or use 2‑stage approach

When testing for thrombophilias after a VTE event, use either a two-stage testing approach or perform testing only after a minimum of 3 months of completed anticoagulant therapy and after anticoagulants have been held to avoid spurious results.

• Do not perform testing at the time of VTE diagnosis or during the initial 3-month anticoagulant course.
• Two-stage testing or waiting ≥3 months after therapy completion is recommended per Anticoagulation Forum.

Reference cited guidelines and technical standards

Cite and use the referenced clinical guidelines and technical standards (ACMG, ASH, ACOG, ESC, NICE, Thrombosis Canada, Anticoagulation Forum) to support testing decisions and documentation of medical necessity.

• ACMG recommendations guide genetic testing indications (FVL, prothrombin G20210A).
• ASH, ACOG, ESC/NICE and others provide timing and diagnostic algorithms for D-dimer and imaging.

Denial risk for coding/documentation noncompliance

Claims may be denied or recouped if coding/billing guidelines, reimbursement policies, or required documentation are not followed; ensure compliance with billing and coding requirements when submitting thrombophilia-related claims.

• Follow Uniform Billing, CPT, ICD-10, CMS/NCCI guidance as applicable.
• Inadequate documentation supporting medical necessity can lead to denial or recoupment.

Denial risk for discouraged testing contexts

Ordering thrombophilia testing after a provoked VTE, routine testing of asymptomatic family members, or testing during the acute 3‑month anticoagulation period are contexts multiple authorities advise against and may trigger denial if unsupported by documentation.

• Do not routinely test following provoked VTE; testing is unlikely to change anticoagulation decisions.
• Avoid routine testing of asymptomatic relatives unless results would alter management.

Do not test during acute clot or while on anticoagulation

Avoid ordering thrombophilia tests during an acute clot or while the patient is receiving anticoagulation because natural anticoagulants are consumed during acute thrombosis and anticoagulant therapy can alter levels, producing spurious results.

• Protein C, protein S, and antithrombin levels can be reduced during acute events or by anticoagulants, leading to false-positive/altered results.
• Defer testing per guidance until appropriate interval after therapy is completed.

Policy governance and effective date — follow updated procedures

Publication history shows governance approval on 06/16/2026; providers should follow the updated policy procedures effective 10/01/2026 to avoid administrative or procedural denials.

• Original documentation governance approved 06/16/2026; effective date 10/01/2026.
• Failure to follow updated policy procedures after the effective date may risk administrative denials.

Ordering must follow authorization and medical necessity

Follow authorization and medical necessity guidelines when ordering; targeted testing prior to initiating oral contraceptives may be indicated for individuals with personal or family history of DVT.

Order tests when results will change management

Order thrombophilia tests only when the clinical scenario matches guideline‑supported indications and when results are expected to change management (for example, decisions about anticoagulation duration, pregnancy‑related prophylaxis, or contraceptive choices).

Order tests after clinical triage and specialist consultation when appropriate

Order testing within the context of validated clinical decision rules and seek specialist consultation when results may be affected by anticoagulation or when testing could influence management decisions.

Who should order testing — follow guideline context

Clinical guideline context (e.g., ASH, ACOG) should guide who orders testing; the policy does not specify particular authorized orderers.